Overview
US medical device maker's fiscal Q3 revenue rose 8.9%, beating analyst expectations
Adjusted EPS loss for fiscal Q3 narrowed and beat analyst expectations
Company raised full-year guidance for net sales and adjusted EBITDA
Outlook
AngioDynamics raises FY 2026 net sales guidance to $313.5-$315.5 mln from $312-$314 mln
Company lifts FY 2026 adjusted EBITDA forecast to $10-$12 mln from $8-$10 mln
AngioDynamics expects FY 2026 cash flow may be slightly negative due to inventory build
Result Drivers
MED TECH GROWTH - Double-digit growth in Med Tech segment, led by Auryon, mechanical thrombectomy (AlphaVac and AngioVac), and NanoKnife platforms
TARIFFS AND COST INFLATION - Gross margin declined due to tariffs, inflation, and manufacturing transition costs, in line with expectations
OPERATING DISCIPLINE - Profitability supported by disciplined execution of operating initiatives
Company press release: ID:nBwbjKjCGa
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Sales | Beat | $78.4 mln | $76.77 mln (3 Analysts) |
Q3 Adjusted EPS | Beat | -$0.07 | -$0.11 (3 Analysts) |
Q3 Adjusted Net Income | Beat | -$3 mln | -$4.45 mln (3 Analysts) |
Q3 Net Income | -$8.1 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for AngioDynamics Inc is $18.00, about 50.8% above its April 1 closing price of $11.94
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Comments